StockData
Guardant Health, Inc. logo

Guardant Health, Inc. (GH) KPIs and segments

GHNasdaqServices-Medical LaboratoriesFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 10/30
$143.28−0.75 (-0.52%)

Close on Nov 17, 2026Market cap $19.23BP/E –Yield –

KPI & bộ phận

Chỉ số vận hành và bộ phận làm nên hoạt động của Guardant Health · năm tài chính kết thúc ngày 31 tháng 12

Nhìn nhanh KPI của Guardant Health: 39 chỉ số vận hành, trong đó có Oncology Clinical Test Volume, Shield Colorectal Cancer Screening Test Volume và Biopharma Test Volume, lấy từ 590 tài liệu nguồn, cùng doanh thu theo bộ phận, sản phẩm và khu vực từ hồ sơ SEC. Mỗi số đều dẫn tới tài liệu gốc. Tất cả chỉ số hiện cả bảng; Cốt lõi chỉ giữ bộ phận và KPI nổi bật. Bảng bộ phận còn có cách xem lũy kế 12 tháng.

Biểu đồ đang trống. Tick vào ô cạnh bất kỳ chỉ số nào ở bảng dưới để vẽ — tick nhiều chỉ số để so sánh trên cùng một biểu đồ.

Bộ phận, KPI nổi bật và mọi chỉ số vận hành từ hồ sơ, thông cáo kết quả và bản trình bày.

Thêm vào biểu đồChỉ số
Q3 2026
Q2 2026
Q1 2026
Q4 2025
Q3 2025
Q2 2025
Q1 2025
Q4 2024
Q3 2024
Q2 2024
Q1 2024
Q4 2023
Oncology($M)
219205190184159151146141130126
Biopharma and data($M)
60.953.054.054.756.045.449.546.543.937.6
Screening($M)
52.941.635.124.114.85.684.121.0000
Licensing and other($M)
2.062.142.181.952.571.862.572.733.035.16
United States($M)
318285264249217194192180168157143
International($M)
16.917.017.715.815.49.8610.211.49.1211.112.4
Oncology Clinical Test Volume1
117,000104,00086,00079,00074,00064,00059,00057,30053,10049,40046,90046,400
Oncology Clinical Test Volume Growth (YoY)(%)
58.0%63.0%47.0%38.0%40.0%30.0%25.0%24.0%21.0%14.0%20.0%29.0%
Shield Colorectal Cancer Screening Test Volume1
83,00066,00044,00038,00024,00016,0009,0006,400
Shield Non-GAAP Cost per Test($)
330410420520
Biopharma Test Volume (Legacy, Discontinued After Q4 2024)1
11,05010,50010,4758,4509,500
Biopharma Test Volume Growth (YoY, Legacy Through Q4 2024)(%)
16.0%40.0%56.0%37.0%16.0%
Total Revenue($M)
361335302281265232204202192177169155
Out-of-Period Revenue (Prior-Period Performance Obligations)($M)
8.4014.3227.9016.88.9012.23.4018.215.215.82
Total Deferred Revenue (Contract Liabilities)($M)2
45.15256.759.756.460.74441.632.535.427.822.9
Current Deferred Revenue($M)
38.144.847.850.846.954.436.335.529.629.422.618
Long-Term Deferred Revenue($M)
77.208.9099.506.407.706.10365.305
Precision Oncology Testing Revenue (Legacy, Through Q4 2024)($M)1
185181167156142
Development Services & Other Revenue (Legacy, Through Q4 2024)($M)1
17.210.910.712.312.9
Non-GAAP Gross Profit($M)3
24022320018517415413112612110710594.5
Non-GAAP Gross Margin(%)
67.0%67.0%66.0%66.0%66.0%66.0%65.0%63.0%63.0%60.0%63.0%61.0%
GAAP Gross Margin (Reported)(%)
65.0%65.0%65.0%65.0%65.0%65.0%63.0%62.0%61.0%59.0%61.0%60.0%
Non-GAAP Cost of Revenue($M)
12111210295.890.978.372.275.470.470.463.2
Non-GAAP Operating Loss($M)3
-47.2-65.2-68-74.6-54.5-61.5-68.3-88.3-66.3-71.9-71.2-88.5
Non-GAAP Research & Development Expense($M)
84.980.576.685.975.872.574.981.168.47373.480
Non-GAAP Sales & Marketing Expense($M)
15917215413111610894.195.884.674.673.172.7
Non-GAAP General & Administrative Expense($M)
43.435.43743.537.134.930.637.834.431.23030.4
Adjusted EBITDA($M)1
-37.3-55.9-58.9-64.9-45.5-51.9-58.5-78.4-56.2-61.9-61.1-78.4
Stock-Based Compensation & Payroll Tax Adjustment($M)
-3.90-3.90-3.20-3.50-2.60-2.80-2.40-2-3.90-1.80-1.80-1.20
Non-GAAP Net Loss($M)1
-38.8-56.2-58.7-63.8-48.3-55-61.1-77.3-55-58.5-56.4-75.9
Non-GAAP Diluted Net Loss per Share($)
-0.29-0.42-0.45-0.50-0.39-0.44-0.49-0.62-0.45-0.48-0.46-0.64
Company-Reported Free Cash Flow($M)
-37.2-69.5-71.2-54.2-45.8-65.9-67.1-83.4-55.3-99.1-37.2-82.8
Full-Year Total Revenue Guidance — Low End($M)11
1,3601,3401,3001,250965915880850720655
Property & Equipment, Gross($M)7
376370355345316311305302282279276272
Laboratory Machinery & Sequencing Equipment (Gross)($M)
165159154144139136132125125124120118
Laboratory & Facility Leasehold Improvements (Gross)($M)
119112111108105105104104103103103102
Computer Hardware & Bioinformatics Infrastructure (Gross)($M)
50.350.343.541.340.538.93736.536.135.234.834.4
Construction in Progress (Gross)($M)
30.738.336.141.321.420.922.328.17.207.408.407.50
Furniture & Fixtures (Gross)($M)
8.508.508.508.508.508.407.907.9087.9088
Capitalized Computer Software (Gross)($M)
222221.701.701.702.10222.10
Accumulated Depreciation($M)
-224-214-205-199-191-185-175-166-157-147-137-127
Total Undiscounted Operating Lease Payments($M)2
214221231238246255215220226229238247
Weighted-Average Remaining Operating Lease Term(năm)
6.06.26.46.76.97.17.27.57.77.98.18.3
Weighted-Average Operating Lease Discount Rate(%)
4.5%4.5%4.5%4.5%4.5%4.5%3.8%3.8%3.8%3.8%3.8%3.9%
U.S. Share of Long-Lived & Right-of-Use Assets(%)
99.0%99.0%99.0%100.0%100.0%100.0%99.0%99.0%99.0%99.0%99.0%98.0%
Cumulative FDA PMA & Supplement Approvals (Guardant Assays)1
504135333027262221191714
New FDA PMA & Supplement Approvals in Period
962331412230
Cumulative Registered Clinical Studies Involving Guardant Assays1
403836363635343434333333
Newly Started Clinical Studies Involving Guardant Assays
220011001002
Natera, Inc. (NTRA) — Revenue($M)1
794753697665592547502476440413368311
Myriad Genetics, Inc. (MYGN) — Revenue($M)1
203191200210206213196211213212202197
Veracyte, Inc. (VCYT) — Revenue($M)1
1521501391411321301141191161149798
CareDx, Inc. (CDNA) — Revenue($M)1
13913211810810087858783927266
Illumina, Inc. (ILMN) — Revenue($M)1
1,1291,1591,0911,1591,0841,0591,0411,1041,0801,1121,0761,119
Quest Diagnostics Inc. (DGX) — Revenue($M)1
3,0973,0432,8952,8062,8162,7612,6522,6212,4882,3972,3662,288
Labcorp Holdings Inc. (LH) — Revenue($M)1
3,8103,7313,5383,5163,5643,5273,3453,3293,2823,2213,1773,033
U.S. Personal Consumption Expenditures: Health Care Services (SAAR)($M)1
3,858,7003,790,3003,699,9003,667,0003,614,9003,529,8003,464,7003,417,8003,358,2003,288,2003,244,4003,159,400
Exact Sciences Corp. (EXAS, Standalone Through Q4 2025) — Revenue($M)1
878851811707713709699638647
GAAP Gross Profit8
Total Assets($M)11
1,8861,9121,9152,0141,2771,3321,3441,4861,5391,6091,7051,786
Operating Cash Flow (GAAP)($M)3
-23.7-57.8-65.6-26.4-35.4-60.3-62.7-64.5-51.1-94-30.3-78.7

In nghiêng là số StockData tự tính từ số đã báo cáo (rê chuột để xem công thức). Số có gạch chân chấm là số đọc từ câu chữ trong thông cáo kết quả và bản trình bày; rê chuột để xem đúng câu đó. Tick vào một dòng để thêm vào biểu đồ phía trên (tối đa 8 đường).

Phương pháp và các chỉ số bị loại
  • Các dòng ở Cốt lõi lấy từ thuyết minh bộ phận và phân tách doanh thu trong hồ sơ 10-K và 10-Q (XBRL), có liên kết tới từng hồ sơ. Số quý 4 bằng cả năm tài chính trừ chín tháng đầu (hiện bằng chữ in nghiêng).
  • Reporting framework transition (Q1 2025): Beginning Q1 2025, Guardant Health replaced its historical two-line revenue presentation (Precision Oncology Testing and Development Services & Other) with four disaggregated product lines (Oncology, Biopharma & Data, Screening, and Licensing & Other). Oncology Clinical Test Volume (excluding Shield) forms a continuous series across both eras, while discontinued Biopharma Test Volume and legacy two-line revenue/cost series are preserved on separate legacy rows through Q4 2024.
  • Quarterly period-splitting derivations: Only cumulative year-to-date GAAP cash flow items (Q2 = 6M − Q1, Q3 = 9M − 6M, Q4 = FY − 9M) and Q4 out-of-period performance obligation revenue / disaggregated footnote lines (Q4 = full year Form 10-K minus nine months Q3 Form 10-Q) are derived by period subtraction; no ratios, sums, or margins are computed.
  • Point-in-time year-end balances: December 31 balance sheet, gross PP&E, deferred revenue, and operating lease figures in Form 10-K / Q4 releases represent both fiscal year-end (FY) and fourth-quarter-end (Q4) balances.
  • Shield colorectal cancer screening: Received FDA Premarket Approval in July 2024, launched commercially in Q4 2024 (6,400 tests), and received CMS Advanced Diagnostic Laboratory Test (ADLT) status at a $1,495 Medicare rate effective April 1, 2025.

Không hiện vì thiếu các kỳ gần đây (7)

  • Product-level ASP ranges (Guardant360 Liquid $3,000–$3,100; Guardant360 Tissue ~$2,000; Guardant Reveal $600–$700; Shield ~$800–$880) — disclosed only intermittently on earnings calls or as ranges rather than continuous exact quarterly series.
  • Implied average revenue per test (Revenue divided by Test Volume) — omitted because blended Oncology revenue includes out-of-period cash collection upsides and Guardant does not publish an audited per-test ASP table.
  • Remaining Performance Obligations (RPO) — Guardant applies the ASC 606-10-50-14 practical expedient for contracts with original expected durations of one year or less and variable consideration; long-term RPO was not continuously disclosed through FY2025.
  • Ordering oncologists, biopharma partner count, patient biobank samples (>1,000,000), Shield covered lives (>80% commercial / ~100 million total in Q3 2026), and total patent portfolio (800+ patents and applications) — communicated primarily as milestone lower bounds ('more than', 'over', '+') rather than exact continuous period-end counts.
  • Medicare share of precision oncology clinical revenue (45% in FY2022, 43% in FY2023, 39% in FY2024) — no longer disclosed on a comparable basis in the FY2025 Form 10-K following the Q1 2025 revenue disaggregation change.
  • Scope 3 indirect value-chain GHG emissions (54,270 mtCO2e in FY2023; 51,463 mtCO2e in FY2024) — omitted because FY2025 Scope 3 calculations remained in progress as of the May 2026 Corporate Responsibility Report Update.
  • Subsidiary standalone operational breakdowns (Guardant Health AMEA, Guardant Health Japan Corp.) — wholly owned subsidiaries are fully consolidated under U.S. GAAP without separate standalone public filings.

Dữ liệu cập nhật 2026-11-07.

Mỗi KPI một trang riêng

Đầy đủ lịch sử, biểu đồ, nguồn và cách trích dẫn cho từng chỉ số

Tài liệu nguồn mới nhất

Các tài liệu được trích nhiều nhất cho số liệu mới nhất của Guardant Health

See a number that looks wrong?